Ruth Itzhaki on China Approves Seaweed Sugar as First New Alzheimer’s Drug in 17 Years
COMMENT The intriguing and encouraging results of the GV971 trial could be explained by an alternative—or perhaps additional—mechanism: the protective effect against AD might well be the consequence of the drug acting as an antiviral agent against HSV1, which has